35714-19-3

Upstream product

• 620-54-2 3-benzylbenzoic acid 
• 17100-67-3 2-<(3-bromobenzyl)oxy>tetrahydro-2H-pyran 
• 52315-08-9 3-benzyl-benzaldehyde 
• 203442-00-6 [3-(hydroxymethyl)phenyl](phenyl)methanol 
• 100-39-0 benzyl bromide 
• 87199-16-4 3-Formylphenylboronic acid 
• 87199-15-3 [3-(hydroxymethyl)phenyl]boronic acid 
• 643-65-2 3-methyl benzophenone 
• 579-18-0 3-benzoylbenzoic acid 
• 1026577-83-2 2-(3-Benzyl-benzyloxy)-tetrahydro-pyran 

Downstream Products

• 69410-45-3 3-benzyl-1-bromomethylbenzene 
• 1028269-03-5 2-{2-[2-(3-Benzyl-benzyl)-benzyl]-benzyloxy}-tetrahydro-pyran 
• 1026185-40-9 2-[2-(3-Benzyl-benzyl)-benzyloxy]-tetrahydro-pyran 
• 148320-05-2 2-<2-(3-Benzylbenzyl)benzyl>benzyl alcohol 
• 148320-04-1 2-(3-Benzylbenzyl)benzyl bromide 
• 148320-03-0 2-(3-Benzylbenzyl)benzyl alcohol 
• 74672-16-5 [3-((phenylmethyl)phenyl)methyl]amine 
• 51629-20-0 3'-benzylbenzyl α-isopropyl-p-methoxyphenylacetate 
• 51630-52-5 3-Methyl-2-p-tolyl-butyric acid 3-benzyl-benzyl ester 
• 51628-93-4 3'-Benzylbenzyl-α-isopropyl-3-methoxy-4-methyl-phenylacetat 
• 51628-78-5 3'-Benzylbenzyl-α-cyano-2-methoxy-phenylacetat 
• 51629-23-3 3'-Benzylbenzyl-α-isopropenyl-4-methoxy-phenylacetat 
• 51630-61-6 2-(4-Isopropyl-phenyl)-3-methyl-butyric acid 3-benzyl-benzyl ester 
• 51629-95-9 2-(4-Bromo-phenyl)-3-methyl-butyric acid 3-benzyl-benzyl ester 

Relevant academic research and scientific papers

SMALL MOLECULE ANTAGONIST COMPOUND TAC5 SERIES HAVING TOLL-LIKE RECEPTOR 3/7/8/9 INHIBITORY FUNCTION

A small molecule antagonist compound having a toll-like receptor 3/7/8/9 inhibitory function and its use in inhibiting TLR7, TLR8, TLR9 and TLR3 are disclosed. A novel compound expressed by TAC5 and TAC5-a, TAC5-c, TAC5-d or TAC5-e which are derivatives thereof not only prevents TNFα secretion, NFkB activation, IkB degradation and MAPKs phosphorylation induced by poly(I:C) (TLR3 agonist), IMQ (TLR7 agonist), CL075 (TLR7/8 agonist), R848 (TLR7/8 agonist), TL8 (TLR8 agonist) or CpG ODN (TLR9 agonist), but also inhibits generation of inflammatory cytokine, and thus is highly advantageous for preventive or therapeutic use for TLR3/7/8/9-related autoimmune diseases and inflammatory diseases including systemic lupus erythematosus, psoriasis and the like.

Probing the Hydrophobic Binding Pocket of G-Protein-Coupled Lysophosphatidylserine Receptor GPR34/LPS1 by Docking-Aided Structure-Activity Analysis

The ligands of certain G-protein-coupled receptors (GPCRs) have been identified as endogenous lipids, such as lysophosphatidylserine (LysoPS). Here, we analyzed the molecular basis of the structure-activity relationship of ligands of GPR34, one of the LysoPS receptor subtypes, focusing on recognition of the long-chain fatty acid moiety by the hydrophobic pocket. By introducing benzene ring(s) into the fatty acid moiety of 2-deoxy-LysoPS, we explored the binding site's preference for the hydrophobic shape. A tribenzene-containing fatty acid surrogate with modifications of the terminal aromatic moiety showed potent agonistic activity toward GPR34. Computational docking of these derivatives with a homology modeling/molecular dynamics-based virtual binding site of GPR34 indicated that a kink in the benzene-based lipid surrogates matches the L-shaped hydrophobic pocket of GPR34. A tetrabenzene-based lipid analogue bearing a bulky tert-butyl group at the 4-position of the terminal benzene ring exhibited potent GPR34 agonistic activity, validating the present hydrophobic binding pocket model.

CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS

Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.

Iron-catalyzed reductive dehydroxylation of benzylic alcohols using polymethylhydrosiloxane (PMHS)

The combination of FeCl3 and PMHS is an efficient reducing system for the selective dehydroxylation of secondary benzylic alcohols, even in the presence of carbonyls, under very mild conditions. Georg Thieme Verlag Stuttgart · New York.

MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF

Provided are compounds that are modulators of C3a receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, the compounds are pyridones. In certain embodiments, provided are methods for treatment or amelioration of diseases associated with modulation of C3a receptor activity.

Chemistry and stereochemistry of benzyl-benzyl interactions in MH+ ions of dibenzyl esters upon chemical ionization and collision-induced dissociation conditions

Isobutane chemical ionization mass spectra of dibenzyl esters of a wide variety of aliphatic, olefinic, alicyclic and aromatic dicarboxylic acids exhibit abundant m/z 181 C14H13+ ions, indicating a highly general rearrangement process involving the formation of a new bond between the two benzyl groups. An extensive collision-induced dissociation and deuterium labeling study suggested that these ions are an almost equimolar mixture of isomeric α-o-tolylbenzyl, α-p-tolylbenzyl and p-benzylbenzyl cation structures, and this composition is identical for all the diesters examined. This structural assignment of the C14H13 ions suggests a mechanistic pathway for their generation, based on the formation of the new bond between the benzyl methylene group of the protonated benzoxycarbonyl and the phenyl ring of the other ester moiety via π- (and/or ion-neutral) and α-complexes. Stereoisomeric diesters show an unusual steric effect: trans-isomers give rise to much more abundant C14H13+ ions than the cis counterparts. This behavior is explained by stabilized proton-bridged structures of the MH+ ions of the cis-isomers.

Heterocyclic chemistry

The present invention relates to therapeutically active azaheterocyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating a central nervous system ailment related to the GABA uptake.

Insecticidal ethers

This invention relates to novel fluorinated ethers, useful as insecticides and acaricides, to processes and intermediates for their preparation, to insecticidal and acaricidal compositions thereof and to methods of combating and controlling insect and acarine pests therewith.

Biscyclophanes. Part 2: Regioselectivity in the Acid-catalysed Cycloalkylation of Benzylbenzylic Alcohol (BBA)

o-Benzylbenzylic alcohols (o-BBAs), in which the terminnal benzyl alcohol is substituted by repeating benzyl chains all in the ortho sense, have been found to have conspicuous regioselectivity in acid-catalysed cycloalkylation, giving rise to various cycl